Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4Unknown 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 220Lymphoid 144Other hematologic neoplasm 96Myeloid 16Genitourinary 14Dermatologic 11Gastrointestinal 9Classical hematology 6CNS 6Tumor-Agnostic 4Sarcoma 4Head & Neck 4Other solid neoplasm 3Gynecologic 3Thoracic 2Endocrine 2NET 1Breast 1

Conditions

Neoplasms 4

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 32Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Lenalidomide × Tumor-Agnostic × Clear all
NCT03113695 2022-07-05

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

University of California, San Diego

Phase 1 Completed
4 enrolled
Tumor-Agnostic

Neoplasms

NCT02721043 2021-01-11

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Neoplasms

NCT00046735 2019-11-18

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Celgene

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

NCT01750983 2019-02-25

Ipilimumab and Lenalidomide in Advanced Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
101 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡